NCT06767813 2025-09-19
Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Recruiting
Clinical Trials
12 trialsNCT04207463 2020-06-17
A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Unknown
NCT04291248 2020-03-02
A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Unknown
NCT04216082 2020-01-02
A Study of Anlotinib in Subjects With Advanced Malignancy
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Completed
NCT04106024 2019-09-26
Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial
Cttq
Phase 2 Unknown
NCT01878448 2019-05-22
ALTN/STS
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Completed
NCT01874873 2019-05-21
ALTN/MTC
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Completed
NCT03527888 2019-05-21
Study of Anlotinib in Patients With Primary Malignant Bone Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Unknown
NCT03059797 2019-05-16
Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Completed
NCT02072044 2017-12-29
Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Unknown
NCT02809534 2016-09-07
ALTER0802
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Unknown
NCT01924195 2015-10-28
Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Completed